Aspirin for primary prevention of cardiovascular events

Journal of General Internal Medicine

Volumn 13, Issue 12, 1998, Pages 824-835

  Augustovski, Federico A ^a   Cantor, Scott B ^b,e   Thach, Chau T ^c   Spann, Stephen J ^d  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Aspirin; Cardiovascular disease; Decision analysis; Primary prevention; Risk stratification

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; DIGESTIVE SYSTEM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MALE; MEDICAL DECISION MAKING; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; STROKE;

ASPIRIN; CARDIOVASCULAR DISEASES; DECISION SUPPORT TECHNIQUES; HUMANS; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 0032433662     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1998.00246.x     Document Type: Article

References (34)

1. United States Preventive Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams and Wilkins; 1996.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in varions categories of patients. BMJ. 1994;308:81-106.
3. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994; 330:1287-94.
4. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet. 1998;351:233-41.
5. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
6. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. Circulation. 1991;83:356-62.
7. Steering Committee of the Physician's Health Study Research Group. Final report of the aspirin component of the ongoing Physician's Health Study. N Engl J Med. 1989;321:129-35.
8. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-6.
9. Wolf PA, D'Agostino RB, Belange AJ, Kennel WB. Probability of stroke: a risk profile from Framingham study. Stroke. 1991;22:312-8.
10. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521-7.
11. Wilson PW, Evans JC. Coronary artery disease prediction. Am J Hypertens. 1993;6:5309-13.
12. Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease: the Framingham experience. Cardiology. 1993;82: 137-52.
13. Leaverton PE, Sorlie PD, Kleinman JC, et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chron Dis. 1987;40: 775-84.
14. The Salt Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345-9.
15. Giovanueci E, Rim EB, Stampfer MS, Colditz GA, Aschero A, Willer WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241-6.
16. Orencia A, Bailey K, Yawn BP, Kottke TE. Effect of gender on long term outcome of angina pectoris and myocardial infarction/sudden unexpected death. JAMA. 1993;269:2392-7.
17. Beck JR. Technical note. Med Decis Making. 1989;9:150.
18. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health. 1987;77:1417-26.
19. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis A. Short and long term prognosis of acute myocardial infarction since the introduction of thrombolysis. BMJ. 1993;307:349-53.
20. Wolf PA, D'Agostino EB, O'Neal A, et al. Secular trends in stroke incidence and mortality: the Framingham study. Stroke. 1992;23: 1551-5.
21. McGovern PG, Burke GL, Sprafka JM, Xue S, Folsom AR, Blackburn H. Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990: the Minnesota heart survey. JAMA. 1992;268:753-9.
22. Howard G, Toole JF, Becker C, et al. Changes in survival following stroke in five North Carolina counties observed during two different periods. Stroke. 1989;20:345-50.
23. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
24. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology. 1994;44:626-34.
25. Department of Health and Human Services. Vital Statistics of the United States, 1988. Hyattsville, Md: National Center for Health Statistics; 1992.
26. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-49.
27. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-45.
28. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993;13:161-5.
29. Gabriel SE, Campion EM, Fallon WM. Patient preferences for non-steroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis. J Rheumatol. 1993;20:358-61.
30. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update, 6: actylsalicylic acid and the primary prevention of cardiovascular disease. Can Med Assoc J. 1991; 145:1091-5.
31. Fuster V, Dyken ML, Vokonas PS, Hennekens C. AHA Medical/ Scientific Statement: aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-75.
32. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness and side effects. Chest. 1992;102:S327-36.
33. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mamography guidelines to include women 40 to 49 years of age. Ann Intern Med. 1997;127:955-65.
34. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med. 1994;330:1895-6.